Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015

被引:5
作者
Watanabe, Jonathan H. [1 ]
Chau, Diane L. [2 ]
Hirsch, Jan D. [1 ]
机构
[1] Skaggs Sch Pharm & Pharmaceut Sci, Div Clin Pharm, San Diego, CA USA
[2] Univ Calif San Diego, Sch Med, Dept Med, Div Geriatr, La Jolla, CA 92093 USA
基金
美国国家卫生研究院;
关键词
Medications; Medicare; costs; economics; geriatrics; DRUGS;
D O I
10.1111/jgs.15443
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Access to prescription medications is critical as the U.S. population ages. Escalating drug costs have garnered mounting attention from the public with increasing federal scrutiny. The Medicare Part D program will increasingly be relied upon to support the health of our nation's older people. We reviewed the publically available Medicare Part D usage data from 2011 to 2015 to quantify the cost of the 10 costliest medications for Part D, evaluated the number of beneficiaries treated with these medications, and measured beneficiaries' out-of-pocket costs. We observed over the analysis period, an increase in spending for these medications, a reduction in number of patients that received them, with increased out-of-pocket costs for the patient. In 2015 U.S. dollars, the amount Medicare Part D spent on the 10 costliest medications increased from $21.5 billion in 2011 to $28.4 billion in 2015a 32% increase. The number of beneficiaries who received 1 of the 10 costliest medications fell from 12,913,003 in 2011 to 8,818,471a 32% drop, with an average annual decrease of 7.9%. Out of pocket spending by patients that use these medications increased over the study period. For beneficiaries without the low-income subsidy, the average out-of-pocket cost share for 1 of the 10 costliest medications increased from $375 in 2011 to $1,366 in 2015a 264% increase overall and an average 66% increase per year. Specialty medications are a growing portion of the costliest medications. As medication costs continue to escalate, and specialty medications become more common, the U.S. will be increasingly challenged with devising mechanisms to access sustainable, affordable medications for all older adults.
引用
收藏
页码:1621 / 1624
页数:4
相关论文
共 19 条
[1]  
[Anonymous], IS MED D
[2]  
[Anonymous], 2017, MAK MED AFF NAT IMP
[3]  
Burton TM, WALL STREET J
[4]  
Centers for Medicare & Medicaid Services, EL LOW INC SUBS
[5]  
CVS Health, WHATS SPEC SPEC
[6]   Association of Prescription Drug Price Rebates inMedicare Part D With Patient Out-of-Pocket and Federal Spending [J].
Dusetzina, Stacie B. ;
Conti, Rena M. ;
Yu, Nancy L. ;
Bach, Peter B. .
JAMA INTERNAL MEDICINE, 2017, 177 (08) :1185-1188
[7]  
Gaudette Etienne, 2015, Forum Health Econ Policy, V18, P75
[8]  
Henry J, 2017, 10 ESS FACTS MED PRE
[9]  
Henry J., 2017, 10 ESS FACTS MED FIN
[10]  
IQVIA Institute, 2017, MED US SPEND US